Exact Sciences Corporation (NASDAQ:EXAS) had its price objective boosted by research analysts at Jefferies Group LLC to $60.00 in a report issued on Tuesday. The brokerage currently has a “buy” rating on the medical research company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 9.11% from the company’s current price. Jefferies Group also issued estimates for Exact Sciences Corporation’s FY2020 earnings at $1.00 EPS.

Other research analysts have also issued reports about the stock. Vetr raised shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price objective for the company in a research note on Tuesday, July 25th. Lake Street Capital lifted their price objective on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Roth Capital lifted their price objective on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. BTIG Research reaffirmed a “buy” rating and set a $45.00 price objective (up from $35.00) on shares of Exact Sciences Corporation in a research note on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 price objective (up from $42.00) on shares of Exact Sciences Corporation in a research note on Wednesday, July 26th. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.71.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The company had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. Exact Sciences Corporation’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.36) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Exact Sciences Corporation (EXAS) PT Raised to $60.00” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/11/02/exact-sciences-corporation-exas-pt-raised-to-60-00.html.

In other Exact Sciences Corporation news, Director Thomas D. Carey bought 2,500 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the transaction, the director now owns 60,858 shares in the company, valued at $2,294,955.18. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 231,598 shares of company stock valued at $10,182,030. Corporate insiders own 4.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in EXAS. BlackRock Inc. raised its holdings in shares of Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock valued at $160,718,000 after acquiring an additional 6,789,478 shares in the last quarter. Fred Alger Management Inc. bought a new stake in shares of Exact Sciences Corporation in the second quarter valued at about $84,177,000. Lord Abbett & CO. LLC raised its holdings in shares of Exact Sciences Corporation by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after acquiring an additional 875,527 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Exact Sciences Corporation in the second quarter valued at about $29,450,000. Finally, Vanguard Group Inc. raised its holdings in shares of Exact Sciences Corporation by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after acquiring an additional 700,051 shares in the last quarter. Hedge funds and other institutional investors own 85.12% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.